MARATTO

article · Zagazig University Medical Journal

The Efficacy of Excimer Laser in the Treatment of Alopecia Areata

Abstract

Background: Alopecia areata is a widespread, non-scarring, autoimmune T cell-mediated condition that causes patchy hair loss on the scalp and other regions of the body. This study aimed to the efficacy of excimer laser in treatment of alopecia areata. Patients & Methods: Interventional clinical study was conducted among 15 patients diagnosed with scalp alopecia areata, who received their treatment only as one session of excimer laser per week for 3 months. Treatment of alopecia areata was done according to the study protocol and the follow up was made by taking photographs every two sessions for evaluation of the percentage of hair regrowth and calculation of SALT II score difference before and after treatment. Results: the duration of treatment required for achieving the treatment in the studied group excimer alone up to 12 weeks. The complete response to treatment of complete responder (SALT II= 0 after treatment) we recorded 26.7% of the studied group are complete responders (100% hair regrowth) while the non- responders (SALT II before =SALT II after) the studied group recorded a percentage of non-responders (46.7%) hair regrowth =0. Conclusion: Excimer laser is an effective tool in the treatment of patchy alopecia areata of mild to moderate degree.

Research topics

  • Hair Growth and Disorders
  • Dermatologic Treatments and Research
  • melanin and skin pigmentation

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/zumj.2024.297563.3444

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.